Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. (17th May 2019)

• Record Type: Journal Article
• Authors: Bourgi, Kassem; Rebeiro, Peter F; Turner, Megan; Castilho, Jessica L; Hulgan, Todd; Raffanti, Stephen P; Koethe, John R; Sterling, Timothy R
• Is Part Of: Clinical infectious diseases. Volume 70:Number 7(2020)
• Page Start: 1267
• Page End: 1274
• Publication Date: 2019-05-17
• Subjects: integrase strand transfer inhibitors -- treatment-naive adults with HIV -- weight gain -- HIV metabolic complications; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciz407
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: Recent studies have reported weight gain in virologically suppressed persons living with human immunodeficiency virus (PLWH) switched from older antiretroviral therapy (ART) to newer integrase strand transfer inhibitor (INSTI)–based regimens. In this study, we investigated whether weight gain differs among treatment-naive PLWH starting INSTI-based regimens compared to other ART regimens. Methods: Adult, treatment-naive PLWH in the Vanderbilt Comprehensive Care Clinic cohort initiating INSTI-, protease inhibitor (PI)–, and nonnucleoside reverse transcriptase inhibitor (NNRTI)–based ART between January 2007 and June 2016 were included. We used multivariable linear mixed-effects models to generate marginal predictions of weights over time, adjusting for baseline clinical and demographic characteristics. We used restricted cubic splines to relax linearity assumptions and bootstrapping to generate 95% confidence intervals. Results: Among 1152 ART-naive PLWH, 351 initiated INSTI-based regimens (135 dolutegravir, 153 elvitegravir, and 63 raltegravir), 86% were male, and 49% were white. At ART initiation, median age was 35 years, body mass index was 25.1 kg/m 2, and CD4 + T-cell count was 318 cells/μL. Virologic suppression at 18 months was similar between different ART classes. At all examined study time points, weight gain was highest among PLWH starting dolutegravir. At 18 months, PLWH on dolutegravir gained 6.0 kg, compared to 2.6 kg for NNRTIs ( P < .05), and 0.5 kg for elvitegravir ( P < .05). PLWH starting dolutegravir also gained more weight at 18 months compared to raltegravir (3.4 kg) and PIs (4.1 kg), though these differences were not statistically significant. Conclusions: Treatment-naive PLWH starting dolutegravir-based regimens gained significantly more weight at 18 months than those starting NNRTI-based and elvitegravir-based regimens. Abstract : This report evaluates the differences in weight gain among treatment-naive persons living with HIV (PLWH) initiating antiretroviral therapy. The results highlight enhanced weight gain among PLWH starting dolutegravir-based therapy and lower weight gain with elvitegravir-based therapy.